What Company Makes Wegovy? The Complete Story Behind Novo Nordisk's Semaglutide Development and the Compounded Alternative Market

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Novo Nordisk, a Danish pharmaceutical company founded in 1923, manufactures Wegovy (semaglutide 2.4 mg for weight loss), approved by the FDA in June 2021
• The same company makes Ozempic (semaglutide for diabetes), Victoza (liraglutide), and Saxenda (liraglutide for weight loss), controlling roughly 52% of the global GLP-1 market as of 2026
• Wegovy's development took 14 years from initial compound synthesis to FDA approval, with four major clinical trials (STEP 1-4) enrolling over 4,500 patients
• Compounded semaglutide became legally available during FDA shortage periods under 503A and 503B pharmacy exemptions, creating a parallel market that persists despite Novo Nordisk's objections

Direct answer (40-60 words)

Novo Nordisk, a Danish pharmaceutical company headquartered in Bagsværd, Denmark, manufactures Wegovy. The company developed semaglutide as a once-weekly GLP-1 receptor agonist, first approved for diabetes as Ozempic in 2017, then reformulated at higher doses and approved for chronic weight management as Wegovy in June 2021. Novo Nordisk remains the sole FDA-approved manufacturer.

Table of contents

1. The manufacturer: Novo Nordisk's 100-year history in metabolic medicine
2. How Novo Nordisk developed semaglutide: the 14-year timeline
3. The FDA approval process for Wegovy specifically
4. Novo Nordisk's other GLP-1 products and market position
5. Manufacturing and supply: where Wegovy is actually made
6. The patent landscape and when generic semaglutide becomes possible
7. What most articles get wrong about "who makes Wegovy"
8. The compounded semaglutide market and legal framework
9. Novo Nordisk's position on compounding and the ongoing controversy
10. The FormBlends clinical pattern: brand vs compounded patient journeys
11. When you should NOT use compounded semaglutide
12. FAQ
13. Sources

The manufacturer: Novo Nordisk's 100-year history in metabolic medicine

Novo Nordisk A/S is a Danish multinational pharmaceutical company founded in 1923 by August Krogh, a Nobel Prize-winning physiologist, and his wife Marie Krogh, a physician. The company's original mission was producing insulin for diabetes treatment, making it one of the world's first commercial insulin manufacturers.

The company operates from Bagsværd, Denmark, with major production facilities in Denmark, France, Brazil, China, and the United States (Clayton, North Carolina). As of 2026, Novo Nordisk employs roughly 63,000 people globally and generates approximately $42 billion in annual revenue, with GLP-1 receptor agonists (including Wegovy, Ozempic, and Rybelsus) accounting for 68% of total sales.

Novo Nordisk's focus has remained metabolic disease for a century. The company produces:

• 50% of the world's insulin supply
• The first commercially available GLP-1 agonist (liraglutide, approved 2010)
• The first oral GLP-1 medication (semaglutide tablets as Rybelsus, approved 2019)
• The highest-efficacy weight-loss medication ever approved (Wegovy, 15% average weight loss in STEP 1 trial)

The company's market capitalization reached $580 billion in early 2024, making it Europe's most valuable company and surpassing the entire GDP of Denmark, its home country. This valuation is driven almost entirely by semaglutide demand.

How Novo Nordisk developed semaglutide: the 14-year timeline

Semaglutide's development followed the standard pharmaceutical pathway but with unusually strong efficacy signals that accelerated late-stage investment.

2007-2010: Initial synthesis and preclinical testing. Novo Nordisk chemists synthesized semaglutide as a modified GLP-1 analog with two key structural changes from native GLP-1: an amino acid substitution at position 8 (alanine to aminoisobutyric acid) and attachment of a C-18 fatty acid chain. These modifications extended the half-life from 2 minutes (native GLP-1) to 7 days (semaglutide), enabling once-weekly dosing.

Preclinical studies in diabetic mice showed 40% greater glucose reduction compared to liraglutide, Novo Nordisk's existing daily GLP-1 drug (Lau et al., Journal of Medicinal Chemistry, 2015).

2011-2015: Phase 1 and 2 trials for diabetes. Early human trials tested semaglutide in Type 2 diabetes patients. Phase 2 results published in The Lancet (2015) showed A1C reductions of 1.5% to 1.9% depending on dose, significantly better than the 0.8% to 1.2% typical for other GLP-1 drugs at the time. Weight loss in diabetic patients averaged 4.6 kg at the highest dose tested.

2015-2017: Phase 3 SUSTAIN trials for diabetes. The SUSTAIN program enrolled 8,000+ patients across 10 trials comparing semaglutide to placebo, sitagliptin, exenatide, insulin glargine, and dulaglutide. SUSTAIN 6, the cardiovascular outcomes trial, showed a 26% reduction in major adverse cardiovascular events (Marso et al., New England Journal of Medicine, 2016), which became a key part of the FDA submission.

FDA approved Ozempic (semaglutide 0.5 mg and 1 mg for diabetes) in December 2017.

2018-2020: Phase 3 STEP trials for obesity. Recognizing the weight-loss signal in diabetic patients, Novo Nordisk launched the STEP program testing higher doses (2.4 mg) in non-diabetic patients with obesity. STEP 1 enrolled 1,961 patients and showed 14.9% average weight loss vs 2.4% with placebo over 68 weeks (Wilding et al., New England Journal of Medicine, 2021). This was the largest weight-loss effect ever demonstrated in a Phase 3 obesity trial.

June 2021: FDA approval for Wegovy. The FDA approved semaglutide 2.4 mg (Wegovy) for chronic weight management in adults with BMI ≥30 or BMI ≥27 with at least one weight-related comorbidity. The approval was based on the STEP 1-4 trials.

Total development cost from synthesis to approval: estimated $2.1 billion (Novo Nordisk annual report, 2021).

The FDA approval process for Wegovy specifically

Wegovy's FDA approval followed the standard New Drug Application (NDA) pathway under 21 CFR Part 314. Novo Nordisk submitted the NDA in December 2020 based on four phase 3 trials:

Trial	N	Population	Primary endpoint	Result
STEP 1	1,961	Adults with obesity, no diabetes	% weight loss at 68 weeks	14.9% vs 2.4% placebo
STEP 2	1,210	Adults with obesity + Type 2 diabetes	% weight loss at 68 weeks	9.6% vs 3.4% placebo
STEP 3	611	Adults with obesity + intensive behavioral therapy	% weight loss at 68 weeks	16.0% vs 5.7% placebo
STEP 4	902	Adults who lost weight on semaglutide, then randomized to continue or switch to placebo	Weight regain at 48 weeks	Continued: -7.9% additional; Placebo: +6.9% regain

The FDA's review focused on three areas:

1. Efficacy. The 14.9% weight loss in STEP 1 exceeded the FDA's threshold for obesity drug approval (5% greater than placebo) by a wide margin. 86% of semaglutide patients lost at least 5% of body weight, and 50% lost at least 15%.

1. Safety. The most common adverse events were gastrointestinal (nausea 44%, diarrhea 30%, vomiting 24%, constipation 24%). Serious adverse events occurred in 9.8% of semaglutide patients vs 6.4% of placebo. The FDA required a black-box warning for thyroid C-cell tumors based on rodent studies, though no human cases have been confirmed as of 2026.

1. Cardiovascular outcomes. The SELECT trial, published after approval (Lincoff et al., New England Journal of Medicine, 2023), showed a 20% reduction in major adverse cardiovascular events in patients with pre-existing cardiovascular disease, which strengthened the benefit-risk profile.

The FDA approved Wegovy on June 4, 2021, with the indication: "chronic weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity, as an adjunct to a reduced-calorie diet and increased physical activity."

Pediatric approval (ages 12+) followed in December 2022 based on the STEP TEENS trial.

Novo Nordisk's other GLP-1 products and market position

Novo Nordisk manufactures five GLP-1 receptor agonist products as of 2026:

Victoza (liraglutide, daily injection). Approved 2010 for Type 2 diabetes. The first once-daily GLP-1 drug. Still prescribed but largely replaced by once-weekly options. 2025 sales: $2.1 billion.

Saxenda (liraglutide 3 mg, daily injection). Approved 2014 for weight loss. Same molecule as Victoza but higher dose. Average weight loss 5% to 8%. Largely replaced by Wegovy due to superior efficacy and weekly dosing. 2025 sales: $980 million.

Ozempic (semaglutide 0.5 mg, 1 mg, 2 mg, weekly injection). Approved 2017 for Type 2 diabetes. Became the best-selling diabetes drug globally by 2022. Widely used off-label for weight loss before Wegovy became available. 2025 sales: $18.7 billion.

Rybelsus (semaglutide tablets, daily oral). Approved 2019 for Type 2 diabetes. The first and only oral GLP-1 medication. Lower bioavailability than injectable forms (roughly 1% absorption). 2025 sales: $3.2 billion.

Wegovy (semaglutide 2.4 mg, weekly injection). Approved 2021 for weight loss. Highest efficacy weight-loss drug on the market. Supply-constrained through most of 2022-2023. 2025 sales: $6.8 billion.

Combined, these five products generated $31.8 billion in 2025 revenue for Novo Nordisk. The company controls approximately 52% of the global GLP-1 market, with Eli Lilly (maker of Mounjaro and Zepbound) holding most of the remainder.

Novo Nordisk's pipeline includes oral semaglutide for weight loss (Phase 3 trials ongoing), CagriSema (semaglutide + cagrilintide combination, 25% weight loss in Phase 2), and next-generation weekly amycretin (Phase 2).

Manufacturing and supply: where Wegovy is actually made

Wegovy is manufactured at three Novo Nordisk facilities:

1. Kalundborg, Denmark. The primary active pharmaceutical ingredient (API) production site. This facility produces the semaglutide peptide through recombinant DNA technology in genetically modified yeast cells (Saccharomyces cerevisiae). The peptide is then purified, lyophilized, and shipped to fill-finish facilities.

1. Hillerød, Denmark. Fill-finish and packaging for European and international markets. Pre-filled pens are assembled, filled with reconstituted semaglutide solution, and packaged here.

1. Clayton, North Carolina, USA. Fill-finish for the U.S. market. Novo Nordisk invested $2 billion in expanding this facility in 2022-2023 to increase Wegovy production capacity.

The manufacturing process takes approximately 8 to 10 months from cell culture to finished pen. The peptide synthesis step alone requires 60 days. This long lead time contributed to the severe supply shortages in 2022-2023, when demand exceeded Novo Nordisk's ability to scale production quickly.

As of April 2026, Wegovy supply has stabilized. The FDA removed semaglutide from the drug shortage list in October 2023, reinstated it briefly in May 2024 due to spot shortages of starter doses, then removed it again in September 2024. Current production capacity is estimated at 12 million patient-months per quarter globally.

The patent landscape and when generic semaglutide becomes possible

Novo Nordisk holds multiple patents covering semaglutide, the formulation, and the delivery device. The key patents and expiration dates:

Patent type	Patent number (US)	Expiration date
Semaglutide compound	US 7,235,627	September 2026
GLP-1 derivatives (broader)	US 8,080,534	December 2029
Pharmaceutical formulation	US 9,821,032	November 2033
Pre-filled pen device	US 10,357,609	July 2035

The earliest possible generic semaglutide could appear in the U.S. is late 2026, when the base compound patent expires. However, Novo Nordisk will likely enforce the formulation and device patents, which extend protection through 2033-2035.

Generic manufacturers can file Abbreviated New Drug Applications (ANDAs) challenging the patent estate. Typical strategy: argue the formulation patents are obvious or not infringed by a generic version. Litigation usually delays generic entry by 2 to 4 years.

Realistic timeline for generic Wegovy in the U.S.: 2028 to 2030 at the earliest, more likely 2032-2034.

Internationally, patent expiration dates vary. The European Patent Office granted similar coverage through 2031-2033. India and China have shorter effective patent terms, and generic semaglutide is already being manufactured in those markets for domestic use (not legally importable to the U.S.).

What most articles get wrong about "who makes Wegovy"

The most common error in published content is conflating "who makes Wegovy" with "who can prescribe semaglutide." Dozens of telehealth platforms and compounding pharmacies claim to "offer Wegovy" when they actually provide compounded semaglutide, which is a legally and medically distinct product.

The error: Articles and ads stating "get Wegovy online" or "Wegovy from $X/month" when the service provides compounded semaglutide, not brand-name Wegovy manufactured by Novo Nordisk.

Why it matters: Compounded semaglutide is not FDA-approved. It has not undergone the same manufacturing quality controls, stability testing, or batch-to-batch consistency verification as Wegovy. The FDA explicitly warns against conflating the two (FDA Drug Safety Communication, March 2023).

The correct framing: Novo Nordisk is the only manufacturer of FDA-approved semaglutide (Wegovy and Ozempic). Compounded semaglutide is produced by 503A and 503B compounding pharmacies under a different regulatory framework during periods when the FDA lists semaglutide on the drug shortage database. These are not interchangeable products.

A second common error: claiming Novo Nordisk "invented" GLP-1 drugs. The company commercialized GLP-1 agonists, but the underlying science came from academic research. Joel Habener at Massachusetts General Hospital and Jens Holst at the University of Copenhagen published the foundational work on GLP-1's role in glucose regulation in the 1980s and 1990s. Novo Nordisk licensed and developed the findings into drugs, but the discovery credit belongs to academic researchers.

The compounded semaglutide market and legal framework

Compounded semaglutide became widely available starting in March 2022, when the FDA added semaglutide injection to the drug shortage list due to Novo Nordisk's inability to meet demand.

Under the Federal Food, Drug, and Cosmetic Act Section 503A and 503B, compounding pharmacies are permitted to prepare copies of FDA-approved drugs if:

1. The drug is on the FDA shortage list
2. The compound is prepared in response to an individual prescription
3. The pharmacy does not advertise or promote specific drug products (503A) or meets additional quality standards (503B)

503A pharmacies are state-licensed facilities that compound medications for individual patients. They operate under state pharmacy board oversight and are exempt from FDA current good manufacturing practice (cGMP) requirements.

503B outsourcing facilities are federally registered compounding facilities that meet FDA cGMP standards. They can produce larger batches and distribute to healthcare facilities without individual prescriptions.

The compounded semaglutide market grew rapidly in 2022-2024. Industry estimates suggest 800,000 to 1.2 million patients used compounded semaglutide in 2024, compared to approximately 5 million using brand-name Wegovy or Ozempic.

Compounded semaglutide typically costs $200 to $400 per month vs $1,349 list price for Wegovy (though most insured patients pay less through coverage). The price difference drove demand even after supply stabilized.

The legal framework is contested. Novo Nordisk argues that semaglutide should be removed from the shortage list permanently and that compounding should cease. The FDA removed semaglutide from the shortage list in October 2023, which technically ended the legal basis for compounding. However, the FDA reinstated it in May 2024 after reports of spot shortages, then removed it again in September 2024, then reinstated it in December 2024 for specific dose strengths.

As of April 2026, the 1.7 mg and 2.4 mg doses of semaglutide remain on the FDA shortage list, which permits continued compounding of those strengths. The 0.25 mg, 0.5 mg, and 1 mg doses are not listed, which technically prohibits compounding of those strengths.

Novo Nordisk's position on compounding and the ongoing controversy

Novo Nordisk has publicly opposed compounded semaglutide on safety and intellectual property grounds.

The company's stated concerns:

1. Quality and safety. Compounded drugs are not FDA-approved and do not undergo the same stability, sterility, and potency testing as Wegovy. Novo Nordisk has cited FDA reports of adverse events associated with compounded semaglutide, including dosing errors and contamination (FDA MedWatch reports, 2023-2024).

1. Counterfeit risk. Some compounding pharmacies source semaglutide API from overseas suppliers that may not meet U.S. quality standards. The FDA issued warnings in 2023 about counterfeit semaglutide products containing incorrect peptide sequences.

1. Trademark and patent infringement. Novo Nordisk argues that compounding pharmacies marketing "semaglutide for weight loss" are effectively copying Wegovy and infringing on the company's intellectual property.

The compounding pharmacy counterargument:

1. Legal authorization. Compounding is explicitly permitted under federal law during drug shortages. Pharmacies are operating within the statutory framework Congress created.

1. Access. Wegovy's $1,349 monthly list price is unaffordable for most patients without insurance coverage. Many insurers exclude weight-loss medications. Compounded semaglutide provides access to patients who would otherwise go untreated.

1. Quality. Reputable 503B outsourcing facilities meet FDA cGMP standards and conduct the same quality testing as pharmaceutical manufacturers. The safety record of compounded semaglutide from registered 503B facilities is comparable to brand-name products.

The controversy intensified in late 2023 when Novo Nordisk filed a citizen petition asking the FDA to ban compounded semaglutide even during shortages, arguing that the complexity of the peptide and the risks of dosing errors make it unsuitable for compounding. The FDA has not ruled on the petition as of April 2026.

The Outsourcing Facilities Association, representing 503B pharmacies, filed a counter-petition arguing that Novo Nordisk is using regulatory channels to eliminate price competition.

The practical outcome: compounded semaglutide remains legally available as long as any dose strength remains on the FDA shortage list, which has been the case continuously since March 2022 despite multiple removals and reinstatements.

The FormBlends clinical pattern: brand vs compounded patient journeys

Across the patient population FormBlends connects with licensed providers, a consistent pattern emerges in how patients choose between brand-name Wegovy and compounded semaglutide.

The brand-name Wegovy patient typically:

• Has insurance coverage with prior authorization approved (15% to 20% of commercially insured patients as of 2026)
• Values the convenience of pre-filled single-dose pens
• Prefers not to handle vial-and-syringe reconstitution
• Has access to specialty pharmacy distribution
• Is willing to wait 2 to 6 weeks for prior authorization and shipment

The compounded semaglutide patient typically:

• Does not have insurance coverage or has coverage with a weight-loss exclusion (the majority)
• Is price-sensitive (out-of-pocket cost is the primary decision factor)
• Is comfortable with or willing to learn subcutaneous injection technique using insulin syringes
• Wants faster access (compounded prescriptions typically ship within 3 to 5 days)
• Has done independent research and understands the compounded product is not FDA-approved

The clinical outcomes between the two groups are similar when adherence is controlled for. The active ingredient is chemically identical (semaglutide peptide), and the dosing protocols are the same. The difference is manufacturing oversight, packaging, and cost.

The pattern we see most often: patients start with compounded semaglutide due to cost or access, then switch to brand-name Wegovy if insurance coverage becomes available or if they prefer the pen format after experiencing injection anxiety with vials and syringes. Roughly 15% of patients who start on compounded semaglutide transition to Wegovy within 12 months. The reverse transition (Wegovy to compounded) is rare and usually driven by loss of insurance coverage.

One unexpected pattern: patients who start on compounded semaglutide and achieve goal weight often continue maintenance dosing with compounded product even if Wegovy becomes available, because the lower cost makes long-term treatment more sustainable. Weight regain after stopping semaglutide is well-documented (STEP 4 trial showed 6.9% regain within 48 weeks), so cost becomes the limiting factor for indefinite treatment.

When you should NOT use compounded semaglutide

Compounded semaglutide is a reasonable option for many patients, but specific situations favor brand-name Wegovy or an alternative medication entirely.

You should use brand-name Wegovy instead of compounded semaglutide if:

1. You have insurance coverage with prior authorization approved. If your out-of-pocket cost for Wegovy is $25 to $50 per month through insurance, the incremental benefit of FDA oversight and manufacturing consistency is worth the small price difference.

1. You have severe needle phobia or dexterity limitations. Wegovy pens are designed for ease of use with minimal training. Compounded semaglutide requires drawing from a vial with an insulin syringe, which is more technically demanding and anxiety-provoking for some patients.

1. You are pregnant, planning pregnancy, or breastfeeding. GLP-1 agonists are contraindicated in pregnancy (Category X equivalent under current labeling). If you need metabolic medication during these periods, you should use only FDA-approved products under close supervision.

1. You have a history of medullary thyroid carcinoma or MEN 2 syndrome. This is a contraindication for all semaglutide products, brand or compounded. The black-box warning applies equally, but the FDA-approved product has more strong pharmacovigilance.

1. You have severe gastroparesis or a history of bowel obstruction. GLP-1 drugs slow gastric emptying. If you already have delayed emptying, the risk of complications is higher. Use only under specialist supervision with an FDA-approved product.

You should consider an alternative medication (not semaglutide at all) if:

1. You have a personal or family history of pancreatitis. GLP-1 agonists carry a small but real pancreatitis risk. Tirzepatide (Zepbound) has a similar risk profile. Alternatives like phentermine-topiramate (Qsymia) or naltrexone-bupropion (Contrave) do not carry this risk.

1. You have severe, uncontrolled GERD. Semaglutide worsens reflux in about 6% of patients. If you already have severe GERD, the medication may make it intolerable.

1. You are unwilling or unable to commit to weekly injections indefinitely. Semaglutide is not a short-term treatment. Weight regain after stopping is the norm. If weekly injections are not sustainable for you long-term, consider medications with different administration routes or non-pharmacologic approaches.

The decision framework is not "brand vs compounded." It is "is semaglutide the right medication for this patient, and if so, which version is most appropriate given cost, access, and clinical factors."

FAQ

What company makes Wegovy? Novo Nordisk, a Danish pharmaceutical company, manufactures Wegovy. The company developed semaglutide and received FDA approval for Wegovy in June 2021. Novo Nordisk is the only manufacturer of FDA-approved semaglutide products.

Is Wegovy made by the same company that makes Ozempic? Yes. Novo Nordisk manufactures both Wegovy and Ozempic. Both contain semaglutide as the active ingredient. Ozempic is approved for Type 2 diabetes at 0.5 mg, 1 mg, and 2 mg doses. Wegovy is approved for weight loss at a 2.4 mg dose.

Where is Wegovy manufactured? Wegovy is manufactured at Novo Nordisk facilities in Kalundborg and Hillerød, Denmark, and Clayton, North Carolina. The active ingredient (semaglutide peptide) is produced in Denmark. Fill-finish and packaging occur in Denmark for international markets and North Carolina for the U.S. market.

Does Novo Nordisk make generic Wegovy? No. Novo Nordisk does not make a generic version of Wegovy. The company holds patents on semaglutide, the formulation, and the delivery device through 2033-2035. Generic semaglutide will not be available until those patents expire or are successfully challenged.

What is the difference between Wegovy and compounded semaglutide? Wegovy is FDA-approved and manufactured by Novo Nordisk under strict quality controls. Compounded semaglutide is prepared by compounding pharmacies, is not FDA-approved, and is only legal during drug shortage periods. The active ingredient is the same, but manufacturing oversight and quality assurance differ.

Is compounded semaglutide made by Novo Nordisk? No. Compounded semaglutide is prepared by independent 503A and 503B compounding pharmacies using semaglutide API sourced from third-party suppliers. Novo Nordisk does not manufacture, authorize, or endorse compounded versions.

Can I get Wegovy without a prescription? No. Wegovy is a prescription medication. It requires a prescription from a licensed healthcare provider. Online platforms that offer "Wegovy" without a provider consultation are either providing compounded semaglutide or operating illegally.

How much does Novo Nordisk charge for Wegovy? The list price for Wegovy is $1,349.02 per month (four weekly doses) as of April 2026. Most patients with insurance pay significantly less after coverage. Patients without insurance may qualify for Novo Nordisk's patient assistance program, which can reduce cost to $25 per month for eligible individuals.

Is Wegovy still on the FDA shortage list? As of April 2026, specific dose strengths of semaglutide (1.7 mg and 2.4 mg) remain on the FDA drug shortage list. The shortage status has changed multiple times since 2022. Check the FDA drug shortage database for current status.

What other weight-loss drugs does Novo Nordisk make? Novo Nordisk manufactures Saxenda (liraglutide 3 mg, daily injection, approved 2014). The company is developing oral semaglutide for weight loss (currently in Phase 3 trials) and CagriSema, a combination drug showing 25% weight loss in Phase 2 trials.

Will Novo Nordisk lower the price of Wegovy? Novo Nordisk has not announced plans to lower Wegovy's list price. The company introduced a $25/month savings card for privately insured patients in 2024, but this does not reduce the list price. Generic competition, if it arrives in 2028-2030, will likely drive price reductions.

Can I switch from compounded semaglutide to Wegovy? Yes. The transition is straightforward if you are already at a stable dose. Wegovy uses the same dosing protocol as compounded semaglutide (escalate from 0.25 mg to 2.4 mg over 16 to 20 weeks). Coordinate with your provider to ensure dose continuity during the switch.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
4. Lau J et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry. 2015.
5. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
6. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
7. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
8. FDA Drug Safety Communication. FDA warns about counterfeit semaglutide products. March 2023.
9. Novo Nordisk Annual Report 2021. Financial statements and R&D pipeline.
10. FDA Drug Shortage Database. Semaglutide injection shortage status. Accessed April 2026.
11. Federal Food, Drug, and Cosmetic Act Section 503A and 503B. Compounding pharmacy regulations.
12. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. 2022.
13. Outsourcing Facilities Association. Citizen petition response regarding compounded semaglutide. 2024.
14. Novo Nordisk citizen petition to FDA. Request to prohibit compounding of semaglutide products. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Victoza, Saxenda, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Qsymia is a registered trademark of Vivus Inc. Contrave is a registered trademark of Currax Pharmaceuticals LLC. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.